Past and present of antiobesity agents: Focus on monoamine modulators

• Published in: American journal of health-system pharmacy Vol. 72; no. 9; pp. 697 - 706
• Main Authors: Khorassani, Farah E., Misher, Anne, Garris, Shauna
• Format: Journal Article
• Language: English
• Published: England Copyright American Society of Health-System Pharmacists, Inc. All rights reserved 01.05.2015; Oxford University Press
• Subjects: Anti-obesity agents; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Dosage and administration; Drug Approval; Drug Monitoring - methods; Drug therapy; Forecasts and trends; Health aspects; Humans; Monoamines; Obesity; Obesity - complications; Obesity - drug therapy; Obesity - epidemiology; Patient Selection; Pharmacists - organization & administration; Professional Role; United States; United States Food and Drug Administration; Weight Loss - drug effects; United States
• ISSN: 1079-2082; 1535-2900; 1535-2900
• DOI: 10.2146/ajhp140034

PURPOSE.A review of recently approved antiobesity medications, including their neuropharmacology, efficacy data from clinical trials, and important patient safety considerations, is presented. SUMMARY.Obesity affects roughly 34% of Americans and is associated with increased risks of type 2 diabetes, hypertension, and coronary artery disease, as well as increased mortality and healthcare costs. Most pharmacologic agents used to treat obesity work by modulating monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine. Since the U.S. market withdrawal of agents such as fenfluramine, dexfenfluramine, and sibutramine due to safety concerns, the Food and Drug Administration (FDA) has approved three monoamine modulators for long­term obesity managementthe serotonergic agent lorcaserin (approved by FDA in 2012), a combination product containing phentermine and extended­release (ER) topiramate (also approved in 2012), and another combination product consisting of ER naltrexone and ER bupropion (approved in late 2014). In Phase III trials of the three products, mean weight reductions ranging from 4.7 to 10.2 kg over periods of one and two years were reported, with substantial percentages of patients achieving weight loss of ≥5%. Adverse effects reported among clinical trial participants were generally mild; however, as the trials excluded patients with significant cardiovascular risks (e.g., uncontrolled hypertension, valvular heart disease), cautious patient selection and monitoring are advised. CONCLUSION.Recently approved medications for long­term management of obesity include lorcaserin, phentermine–topiramate, and naltrexone–bupropion. When these drugs are used to facilitate weight loss, pharmacists can play an important role in helping to ensure appropriate patient selection and monitoring.